Drugs / PM00104
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00359294 | May 2006 → Sep 2008 | cancer, lymphoma | PharmaMar | Terminated | No outcome recorded Stop: Enrollment |
| Phase 22 trials | ||||||
| Phase 2 | NCT01222767 | Dec 2010 → Apr 2012 | Askin tumor, extraskeletal Ewing sarcoma | PharmaMar | Completed | No outcome recorded |
| Phase 2 | NCT00900562 | Aug 2009 → Sep 2011 | cervical cancer, endometrial cancer | PharmaMar | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PM00104 | “Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy” NCT01222767 ↗2“Zalypsis (PM00104) (2.5 mg/vial) is provided as a powder for concentrate for solution for infusion” NCT00900562 ↗ |
| Known as | Zalypsis | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00900562 ↗ |
| Modality | Small molecule | — CHEMBL4297453 ↗ |
| Route | Intravenous | “administered intravenously over 1 hour” NCT00359294 ↗ |